Combination Of Viral And Bacterial Antigens (e.g., Multivalent Viral And Bacterial Vaccine, Etc.) Patents (Class 424/201.1)
-
Publication number: 20100047272Abstract: The present invention relates to the use of a mycobacterial heat-shock protein for the manufacture of a vaccine for therapeutic application.Type: ApplicationFiled: October 1, 2007Publication date: February 25, 2010Applicant: Universiteit Utrecht Holding B.V.Inventors: Adriaan Peter Koets, Victor Pierre Marie Gerard Rutten
-
Publication number: 20100040647Abstract: The present invention relates to the field of vaccines for protecting against polio, and in particular to combination vaccines for protecting against polio, diphtheria, tetanus, and pertussis diseases.Type: ApplicationFiled: September 7, 2007Publication date: February 18, 2010Applicant: GlaxoSmithKline Biologicals s.a.Inventors: Herve De Hemptinne, Michel Duchene, Anne Mary, Marc Sonveaux
-
Patent number: 7658934Abstract: The present invention provides vaccines for immunizing a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The vaccine and method employ a full-length, 5?-truncated or 3?-truncated 76 kDa protein of a strain of Chlamydia pneumoniae. Modifications are possible within the scope of this invention.Type: GrantFiled: February 9, 2009Date of Patent: February 9, 2010Assignee: Sanofi Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn
-
Publication number: 20100028379Abstract: This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.Type: ApplicationFiled: November 23, 2007Publication date: February 4, 2010Applicants: PFIZER, INC, PFIZER PRODUCTS INC.Inventors: Cassius M. Tucker, John David Haworth
-
Publication number: 20100021497Abstract: The invention provides a process for producing a combined vaccine containing an inactivated Sabin strain of poliovirus, a Bordetella pertussis protective antigen, a diphtheria toxoid and a tetanus toxoid, the process including a step of producing a high-titer Sabin strain poliovirus. The inventive process for producing a combined vaccine, including a step of culturing, in the presence of from about 4 g/L to about 6 g/L of a microcarrier, Vero cells to be inoculated with a Sabin strain of poliovirus, is useful as a process for efficiently producing a combined vaccine containing an inactivated Sabin strain of poliovirus.Type: ApplicationFiled: September 28, 2007Publication date: January 28, 2010Inventors: Shinobu Abe, Bunsichi Simizu
-
Publication number: 20100015211Abstract: The present invention relates to methods, polypeptides, and polynucleotides encoding immunogenic identical or analogous HIV polypeptides derived from the same or different strains within an HIV subtype and/or different subtypes. Uses of the polynucleotides and polypeptides in combination approaches for generating immune responses are also described. The combination approaches described herein induce broad and potent immune responses against diverse HIV strains from multiple strains within a given subtype and against diverse subtypes. Formulations of compositions for generating immune responses and methods of use for such compositions are also disclosed.Type: ApplicationFiled: November 1, 2005Publication date: January 21, 2010Inventors: Susan W. Barnett, Indresh K. Srivastrava, Victor Raul Gomez-Roman, Marjorie Robert-Guroff
-
Publication number: 20100008950Abstract: A composition comprised of one or more bacterial proteins that are conserved among members of Bacillus cereus that is capable of inducing an immune response against members of Bacillus cereus group bacteria. The invention also relates to a method of utilizing the composition to induce an immune response.Type: ApplicationFiled: July 10, 2009Publication date: January 14, 2010Inventors: Timothy D. Read, Sanghamitra Mukhopadhyay
-
Patent number: 7641896Abstract: The present invention relates to an immunogen-carrier having immunopotentiating or adjuvant properties. More particularly, the immunogen-carrier is a virus-like particle (VLP) from the family of potexvirus, and most particularly the papaya mosaic virus. The VLP produced by recombinant techniques is in fusion with one of its own proteins a protein immunogen. The above VLP and a protein or a protein extract from a viral, bacterial or parasital pathogen may be used as a vaccine.Type: GrantFiled: July 1, 2003Date of Patent: January 5, 2010Assignee: Folia Biotech Inc.Inventors: Denis Leclerc, Nathalie Majeau, Constantino III Roberto López-Macías
-
Publication number: 20090317423Abstract: Multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of M. hyo infection, preferably M. hyo bacterin, or an immunogenic composition comprising M. hyo bacterin, and at least one immunogenic active component of another disease-causing organism in swine, preferably PCV2 wherein the preferred PCV2 antigen for such a multivalent vaccine is PCV2 ORF 2 protein.Type: ApplicationFiled: January 23, 2009Publication date: December 24, 2009Applicant: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael Roof, Marc Eichmeyer
-
Publication number: 20090304737Abstract: The present invention relates to the use of an immunogenic dose of immunogenic material of Mycoplasma hyopneumoniae and an immunogenic dose of live attenuated PRRS virus for the manufacture of a vaccine, and to a vaccine kit comprising such a vaccine.Type: ApplicationFiled: April 6, 2007Publication date: December 10, 2009Applicant: Intervet International B.V.Inventors: Christa Sibilla Drexler, Maarten Witvliet
-
Patent number: 7622124Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.Type: GrantFiled: January 11, 2007Date of Patent: November 24, 2009Assignee: WyethInventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
-
Patent number: 7595058Abstract: The present invention provides vaccines and methods for immunizing a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The vaccine and method employ a full-length, 5?-truncated or 3?-truncated 76kDa protein of a strain of Chlamydia pneumoniae. Modifications are possible within the scope of this invention.Type: GrantFiled: May 2, 2005Date of Patent: September 29, 2009Assignee: Sanofi Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn
-
Publication number: 20090220525Abstract: The present invention relates to a novel rod-shaped pleiomorphic non-motile Gram-negative bacterium causing a new, deadly, disease in fish, to a microbiological culture comprising said bacterium, to a vaccine comprising said bacterium and methods for the preparation of such a vaccine, to antibodies reactive with said bacterium, to diagnostic test kits and to the use of said bacterium.Type: ApplicationFiled: November 9, 2006Publication date: September 3, 2009Inventor: Are Nylund
-
Publication number: 20090208523Abstract: Vaccine containing a first vaccine, adjuvated with an oil-in-water emulsion comprising 5% squalene, 0.5% polysorbate 80 and 0.5% sorbitan trioleate in aqueous citrate buffer pH 6.5, and a nonadjuvated second vaccine as combination partners for the simultaneous, separate or phased application for immunization against viral, bacterial or parasitic infectious diseases.Type: ApplicationFiled: April 22, 2009Publication date: August 20, 2009Inventor: Michael Broeker
-
Patent number: 7576066Abstract: The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.Type: GrantFiled: July 3, 2003Date of Patent: August 18, 2009Assignee: Coley Pharmaceutical Group, Inc.Inventor: Arthur M. Krieg
-
Publication number: 20090202588Abstract: The present invention relates to nucleic acids comprising: (a) sequences of a replication competent transmissible gastroenteritis virus (TGEV), which sequences encode a TGEV replicase under the control of expression regulatory sequences, wherein the replicase is expressed in a host cell and will initiate replication of the nucleic acid and thus increase the number of nucleic acids in the cell; and (b) a sequence encoding at least one neutralizing epitope of ORF5 of porcine reproductive and respiratory syndrome virus (PRRSV), which sequence includes a disulfide bridge forming residue; and (c) a sequence encoding at least one further polypeptide capable of increasing an immune response against PRRSV. The present invention further relates to vectors, virus particles and host cells comprising these nucleic acids as well as their use for the preparation of vaccines, specifically for the preparation of vaccines.Type: ApplicationFiled: November 30, 2006Publication date: August 13, 2009Inventors: Luis Enjuanes Sanches, Sonia Zuniga Lucas, Isabel Sola Gurpegui, Joan Plana Duran
-
Patent number: 7569553Abstract: The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.Type: GrantFiled: July 3, 2003Date of Patent: August 4, 2009Assignee: Coley Pharmaceutical Group, Inc.Inventor: Arthur M. Krieg
-
Patent number: 7569383Abstract: The invention provides chimeric flavivirus vectors including foreign peptides inserted into the envelope proteins of the vectors and methods of using these vectors.Type: GrantFiled: May 31, 2002Date of Patent: August 4, 2009Assignee: Acambis Inc.Inventors: Harold Kleanthous, Charles Miller, Larisa Oros
-
Patent number: 7563449Abstract: The present invention relates to methods for treating or preventing diseases or disorders in a pregnant cow and calf nursing a pregnant cow caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PIV3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno, Leptospira icterohaemorrhagia, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a safe modified live viral combination vaccine further combined with a multivalent bacterin vaccine.Type: GrantFiled: April 21, 2003Date of Patent: July 21, 2009Assignee: Pfizer Inc,Inventors: Michael A. Ellsworth, Martin D. Ficken, Brian J. Fergen, Cassius M. Tucker
-
Publication number: 20090175902Abstract: The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine) selected from viral, bacterial, fungal, parasitic and/or cancer antigens. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response, in particular a mucosal immune response to an antigenic compound.Type: ApplicationFiled: June 27, 2006Publication date: July 9, 2009Inventors: Haixiang Lin, Lie Tao Victor Li
-
Publication number: 20090175903Abstract: Compositions and methods for making and using therapeutic formulations of measles virus antigens with a Proteosome-based adjuvant are provided. The measles virus antigens may be derived from a variety of sources, such as from recombinant production or from a split antigen preparation. The measles vaccine formulations may be used, for example, in methods for treating or preventing a measles virus infection and eliciting a protective immune response.Type: ApplicationFiled: July 29, 2008Publication date: July 9, 2009Applicants: ID BIOMEDICAL CORPORATION OF QUEBEC, MCGILL UNIVERSITYInventors: Brian J. Ward, David S. Burt, Sophie Chabot
-
Publication number: 20090162397Abstract: Heat treated bacterins, a method of producing heat treated bacterins, and porcine emulsion vaccines prepared from such heat treated bacterins are disclosed.Type: ApplicationFiled: December 15, 2008Publication date: June 25, 2009Applicant: PFIZER INC.Inventors: Mark D. Goodyear, Michael J. Huether, Richard Lee Krebs, Nancee L. Oien
-
Publication number: 20090155305Abstract: When preparing HBsAg for use in a combination vaccine, it is known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification.Type: ApplicationFiled: November 7, 2006Publication date: June 18, 2009Inventor: Mario Contorni
-
Patent number: 7544361Abstract: A heteropentamer composed of a fusion monomer (32) comprising a fusion protein of an antigenic amino acid sequence and an amino acid sequence of a monomer of a mucous membrane-binding protein and a nonfusion monomer (20) of an amino acid sequence of a monomer of a mucous membrane-binding protein. A homopentamer composed of a fusion monomer including a fusion protein of an antigen derived from an envelope protein of Japanese encephalitis virus and an amino acid sequence of a monomer of a mucous membrane-binding protein. These heteropentamer and the homopentamer can be used as a vaccine.Type: GrantFiled: July 23, 2004Date of Patent: June 9, 2009Assignees: Advanced Medical Biological Science Institute Co. Ltd., University of the RyukyusInventors: Takeshi Arakawa, Masanao Kikukawa, Isao Shimabukuro, Masayuki Tadano, Yasunobu Matsumoto, Naotoshi Tsuji, Yoshiya Sato
-
Publication number: 20090130141Abstract: The invention provides for oral compositions for safely stimulating an immune response to mucoadhesive antigens for protection against infectious agents, particularly influenza viruses using heat-labile, mutant Escherichia coli enterotoxins and antigen. Methods of stimulating immune responses and for eliciting IgA antibodies are also provided.Type: ApplicationFiled: November 3, 2008Publication date: May 21, 2009Inventors: John D. Barackman, Gary Ott, Samuel Pine, Derek O'Hagan
-
Publication number: 20090130142Abstract: The present invention relates to the use of bacteria of the species Streptococcus phocae for the manufacture of a vaccine, to methods for the production of such vaccines, to bacteria of the species Streptococcus phocae for use in a vaccine and to methods for the combating of Streptococcus phocae infection in fish.Type: ApplicationFiled: January 16, 2009Publication date: May 21, 2009Applicant: Intervet International B.V.Inventors: Luc Grisez, Ruud Philip Antoon Maria Segers, Chow Yong Ng
-
Publication number: 20090123490Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.Type: ApplicationFiled: July 3, 2008Publication date: May 14, 2009Inventors: Andre Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, Francois Madec
-
Publication number: 20090117152Abstract: Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating M. hyopneumoniae infection. Administration to an animal of one or two doses of an adjuvanted live avirulent M. hyopneumoniae composition disclosed herein is effective in providing immunity to the animal and protection from infection with a virulent strain of M. hyopneumoniae thereby reducing the severity of and/or preventing disease caused by one or more virulent strain of M. hyopneumoniae. Also provided are compositions, which further comprise one or more antigen such as, for example, one or more live bacteria, bacterin, toxoid, and/or virus and/or viral antigen. Exemplified are immunogenic compositions, comprising an adjuvanted live avirulent M.Type: ApplicationFiled: November 5, 2008Publication date: May 7, 2009Applicant: WyethInventors: Hsien-Jue Chu, Zhichang Xu, Wumin Li, Nicole Rae Gibson
-
Publication number: 20090117148Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.Type: ApplicationFiled: January 9, 2009Publication date: May 7, 2009Applicant: Corporate Intellectual Property R338Inventor: Paolo Costantino
-
Publication number: 20090110697Abstract: This invention related to a method of immunizing cattle to reduce the effects of infection by bovine herpes virus 1, including abortion and stillbirth, by administering inactivated bovine herpes virus 1 prior to breeding.Type: ApplicationFiled: October 31, 2008Publication date: April 30, 2009Applicant: Novartis AGInventor: John Mateland Herbert
-
Publication number: 20090104226Abstract: Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as well as to method of making and using these immunogenic compositions.Type: ApplicationFiled: May 20, 2005Publication date: April 23, 2009Applicant: NOVARTIS VACCINES AND DIAGNOSTICS INC.Inventors: Silvia Perri, John Polo, Yasushi Uematsu, Catherine Greer
-
Patent number: 7521060Abstract: The invention belongs to the field of animal health and in particular the causative agent of a new bacterial poultry disease, Gallibacterium. The invention provides said Gallibacterium bacteria, vaccine comprising inactivated Gallibacterium, and a method of immunizing to prevent disease in poultry.Type: GrantFiled: October 24, 2002Date of Patent: April 21, 2009Assignee: Boehringer Ingelheim Vetmedica S.A. de C.V.Inventors: Raul Campogarrido, Carlos Gonzalez-Hernandez, Vaithianathan Sivanandan, Maria Elena Vazquez
-
Publication number: 20090098157Abstract: A sterile immunogenic preparation of three purified H. pylori antigens (CagA, VacA and NAP) adjuvanted with alum in an isotonic buffer solution for intramuscular injection. The antigens may be administered in conjunction with antibiotics and/or antisecretories. Urease breath testing, stool antigen testing, and/or immunological analysis may be used as correlate(s) of protection against H. pylori infection. Urea may be used to improve VacA solubility.Type: ApplicationFiled: September 19, 2008Publication date: April 16, 2009Applicant: Novartis Vaccines and Diagnostics s.r.I.Inventor: Giuseppe Del Giudice
-
Publication number: 20090092636Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein.Type: ApplicationFiled: June 11, 2008Publication date: April 9, 2009Applicant: BOEHRINGER INGELHEIM VETMEDICA, INCInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
-
Publication number: 20090087451Abstract: The invention provides kits, methods and compositions of matter which improve the safety of vaccination. By combining the administration of antiviral drugs, particularly ester derivatives of cidofovir, with the administration of viral vaccines, particularly the variola vaccine DryVax, side effects of the vaccine are diminished without significantly affecting the effectiveness of the vaccine.Type: ApplicationFiled: May 26, 2005Publication date: April 2, 2009Applicant: SAINT LOUIS UNIVERSITYInventor: Robert Mark Buller
-
Publication number: 20090068223Abstract: The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the prophylaxis and treatment of BVDV caused infections, and a further immunological active component for the prophylaxis and treatment of microbiological infections other than BVDV.Type: ApplicationFiled: November 13, 2006Publication date: March 12, 2009Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Gregor Meyers, Jeffrey Knittel, Knut Elbers, Rob Tremblay, Craig Jones
-
Patent number: 7501128Abstract: A vaccine comprises a portion of IHNV G protein and a portion of a second protein from a fish pathogen, or their respective nucleic acid coding sequences. The presence of the IHNV G protein boosts the immune response to the second protein, resulting in a protective effect against infection by the fish pathogen and/or mortality caused by the fish pathogen from which the second protein is derived.Type: GrantFiled: March 17, 2005Date of Patent: March 10, 2009Assignee: Novartis Animal Health US, Inc.Inventors: Nathalie C Simard, Linda M Bootland
-
Publication number: 20090053262Abstract: The present invention relates to a combination vaccine for the protection of poultry against Ornithobacterium rhinotracheale, to the use of a live over-attenuated Ornithobacterium rhinotracheale strain and a live attenuated poultry virus for the manufacturing of such a combination vaccine, to methods for the preparation of said combination vaccine and to vaccination kits for the immunization of poultry against Ornithobacterium rhinotracheale.Type: ApplicationFiled: December 21, 2004Publication date: February 26, 2009Applicant: Intervet International B.V.Inventors: Antonius Arnoldus Christiaan Jacobs, Paul Cornelius Maria van Empel, Petrus Johannes Maria Nuijten
-
Publication number: 20090053228Abstract: The present invention relates i.a. to nucleic acids encoding novel Lawsonia intracellularis proteins. It furthermore relates to DNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Also it relates to host cells comprising such nucleic acids, DNA fragments, recombinant DNA molecules and live recombinant carriers. Moreover, the invention relates to proteins encoded by these nucleotide sequences and to their use for the manufacturing of vaccines. The invention also relates to vaccines for combating Lawsonia intracellularis infections and methods for the preparation thereof. Finally the invention relates to diagnostic tests for the detection of Lawsonia intracellularis antigens and of antibodies against Lawsonia intracellularis.Type: ApplicationFiled: January 18, 2005Publication date: February 26, 2009Inventor: Paul Vermeij
-
Publication number: 20080311151Abstract: The present invention relates to novel bacterial isolates identified by their 16S rRNA DNA, that cause periodontal disease in companion animals, polynucleotide sequences contained therein, polypeptides encoded by such polynucleotide sequences and vaccines comprising such bacteria, polynucleotides, or polypeptides. Also provided are methods for treating and preventing periodontal disease and kits for detecting and treating periodontal disease kits for detecting and preventing periodontal disease. In addition, methods for assessing the efficacy of a vaccine against periodontal diseases in an animal are provided.Type: ApplicationFiled: May 12, 2008Publication date: December 18, 2008Applicants: PFIZER, INC., PFIZER PRODUCTS, INC.Inventors: John Morgan Hardham, Kendall Wayne King, Rajendra Krishnan, Kimberly Jean Dreier, David Ross McGavin, John David Haworth
-
Publication number: 20080311147Abstract: Rabies virus (RV) nucleoprotein (N) tightly encapsidates the genomic and antigenomic RNA thereby forming the ribonucleoprotein (RNP) complex. Antigens presented in a rigid and repetitive organization are sufficient to activate B cells to proliferate. In addition to the repetitive organization, it has been shown that RV N protein induces potent T-helper responses resulting in long-lasting and strong humoral immune responses against RV. The possibility to directly manipulate the genome of RV allows us to examine whether the immunogenicity of foreign antigens can be enhanced via incorporation into the RNP structure. A recombinant RV expressing an RV N-green fluorescent protein (GFP) fusion protein. The chimeric N-GFP fusion protein was efficiently expressed and incorporated into RV RNP and virions. Moreover, the recombinant RNP induces a strong humoral immune response against GFP in mice.Type: ApplicationFiled: April 19, 2005Publication date: December 18, 2008Applicant: Thomas Jeffeson UniversityInventors: Matthias J. Schnell, Bernhard Dietzschold
-
Patent number: 7455843Abstract: The present invention describes the adjuvant activity of mutants of LT-IIa and LT-IIb enterotoxin which lack ganglioside binding activity. The adjuvant activity of the LT-IIb(T13I) mutant is comparable to that of the wild type LT-IIb. The adjuvant activity of LT-IIa(T34I) mutant is also described which exhibits a late onset adjuvant activity. These mutants are useful for enhancing immune response to antigens.Type: GrantFiled: September 27, 2004Date of Patent: November 25, 2008Assignee: Research Foundation of State University of New York, TheInventors: Terry D. Connell, Michael W. Russell, Hesham Nawar, Sergio Arce
-
Publication number: 20080260763Abstract: Methods to obtain expression systems and proteins in a high-throughput protocol by utilizing mixtures of cells cultured from those transformed with a desired nucleotide sequence permit rapid production of protein for use in arrays to assess activity. In one embodiment, the proteins (or peptides) in the array are assessed for their immunological activity with regard to an infectious agent.Type: ApplicationFiled: July 1, 2005Publication date: October 23, 2008Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Philip Felgner, Huw Davies, Xiaowu Liang
-
Publication number: 20080260777Abstract: An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes seven field strains of E. coli, Pseudomona aeruginosa, Aerobacter aerogenes, Salmonella enteritidis, Salmonella typhimurium, Salmonella agona, and Salmonella Kentucky. The antigen, composition can be used alone or in combination with a Marek's Disease vaccine to reduce shedding of E. coli and/or Salmonella bacteria.Type: ApplicationFiled: April 19, 2007Publication date: October 23, 2008Inventor: Konky SOTOMAYOR
-
Publication number: 20080254063Abstract: The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses.Type: ApplicationFiled: June 23, 2008Publication date: October 16, 2008Applicant: PHARMACIA AND UPJOHN COMAPNY LLCInventors: Shelly L. Shields, Hans A. Draayer, Michael J. Huether
-
Patent number: 7431930Abstract: The present invention provides a classic IBDV mutant that additionally comprises virus neutralising epitopes 67 (specific for variant-E IBDV).Type: GrantFiled: March 24, 2004Date of Patent: October 7, 2008Assignee: Intervet International B.V.Inventors: Egbert Mundt, Tobias Letzel, Guntram Paul, Adriaan Antonius Wilhelmus Maria van Loon
-
Publication number: 20080226669Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein.Type: ApplicationFiled: December 28, 2006Publication date: September 18, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
-
Publication number: 20080226670Abstract: This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.Type: ApplicationFiled: November 20, 2007Publication date: September 18, 2008Applicants: WARNER-LAMBERT COMPANY, PFIZER INC.Inventors: Paul J. Dominowski, Joseph C. Frantz, Richard L. Krebs, Shelly L. Shields, Robert Greg Sorensen
-
Publication number: 20080226671Abstract: The invention of novel, effective vaccines against Mycoplasma. bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect of M. bovis infections on milk production, weight gain and animal health. Methods of diagnosing, characterizing and treating M. bovis infections as specific biotypes are also disclosed. Vaccine compositions made in accordance with the invention may be either of the attenuated or inactivated variety. Vaccines may also include antigens from other pathogens so as to provide a protective immunogenic response to diseases other than those caused by M. bovis.Type: ApplicationFiled: October 31, 2007Publication date: September 18, 2008Inventors: Joan D. Leonard, Robert W. Tully
-
Patent number: 7416734Abstract: The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect of M. bovis infections on milk production, weight gain and animal health. Methods of diagnosing, characterizing and treating M. bovis infections as specific biotypes are also disclosed. Vaccine compositions made in accordance with the invention may be either of the attenuated or inactivated variety. Vaccines may also include antigens from other pathogens so as to provide a protective immunogenic response to diseases other than those caused by M. bovis.Type: GrantFiled: April 14, 2004Date of Patent: August 26, 2008Assignee: BiomuneInventors: Joan D. Leonard, Robert W. Tully